This site is for healthcare professionals. If you are a member of the public or a patient then please visit our Colonoscopy site.
Download a hand printable guide to preparing and taking PLENVU®
Download two-day (evening/morning) dosing guide
Download dosing schedules to give to your patients
Download two-day (evening/morning) dosing schedule
Adverse events should be reported to your regulatory agency. Adverse events should also be reported to either your local distributor, Norgine Limited, Norgine House, Moorhall Road, Harefield, Uxbridge, Middlesex, UB9 6NS, United Kingdom or by emailing GPharmacoVigilance@norgine.com.
Registered number 30127007. Copyright Norgine 2018.
Norgine B.V., Antonio Vivaldistraat 150, 1083 HP Amsterdam. The Netherlands.
PLENVU, MOVIPREP, NORGINE and the sail logo are registered trademarks of the Norgine group of companies.
Images of people are for illustrative purposes only. Any persons depicted are models and do not use or personally endorse PLENVU®.
You are currently on the PLENVU® Global website.
Please confirm which site you would like to proceed with below:
GL/PLV/0518/0066a
Watch the full recording of our webinar from the ESGE Connect 2020 virtual congress
Colorectal cancer in young adults: act now
This webinar, led by Prof Raf Bisschops and Prof Helmut Neumann, discusses the best-practice learnings on early onset colorectal cancer (EOCRC) including how to identify patients, the impact of optimised bowel preparation and colonoscopy, as well as supporting patients diagnosed with EOCRC.
Organised and sponsored by Norgine. This webinar is hosted in partnership with ESGE. This webinar is part of the ESGE satellite webinar series.
PLENVU, NORGINE and the sail logo are registered trademarks of the Norgine group of companies.
GL-GE-PLV-2000075. Date of preparation: November 2020.
